Towards the bioequivalence of pressurised metered dose inhalers 2. Aerodynamically equivalent particles (with and without glycerol) exhibit different biopharmaceutical profiles in vitro by Haghi, M et al.
European Journal of Pharmaceutics and Biopharmaceutics 86 (2014) 38–45Contents lists available at SciVerse ScienceDirect
European Journal of Pharmaceutics and Biopharmaceutics
journal homepage: www.elsevier .com/locate /e jpbResearch paperTowards the bioequivalence of pressurised metered dose inhalers 2.
Aerodynamically equivalent particles (with and without glycerol)
exhibit different biopharmaceutical proﬁles in vitro0939-6411/$ - see front matter  2013 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.ejpb.2013.02.020
⇑ Corresponding author. Respiratory Technology, The Woolcock Institute of
Medical Research, The University of Sydney, NSW 2006, Australia. Tel.: +61 2
9114 0350; fax: +61 2 9114 0014.
E-mail address: paul.young@sydney.edu.au (P.M. Young).M. Haghi a,b, M. Bebawy c, P. Colombo d, B. Forbes e, D.A. Lewis f, R. Salama a,b, D. Traini a,b, P.M. Young a,b,⇑
aRespiratory Technology, The Woolcock Institute of Medical Research, The University of Sydney, Australia
bDiscipline of Pharmacology, Faculty Medicine, The University of Sydney, Australia
cGraduate School of Pharmacy Health-Pharmacy, University of Technology Sydney, Sydney, Australia
dDepartment of Pharmacy, University of Parma, Parma, Italy
e Institute of Pharmaceutical Science, King’s College London, London, UK
fChiesi Limited, Chippenham, UK
a r t i c l e i n f oArticle history:








Calu-3a b s t r a c t
Two solution-based pressurised metered dose inhaler (pMDI) formulations were prepared such that they
delivered aerosols with identical mass median aerodynamic diameters, but contained either beclometh-
asone dipropionate (BDP) alone (glycerol-free formulation) or BDP and glycerol in a 1:1 mass ratio (glyc-
erol-containing formulation). The two formulations were deposited onto Calu-3 respiratory epithelial cell
layers cultured at an air interface. Equivalent drug mass (1000 ng or 2000 ng of the formulation) or
equivalent particle number (1000 ng of BDP in the glycerol-containing versus 2000 ng of BDP in the glyc-
erol-free formulation) were deposited as aerosolised particles on the air interfaced surface of the cell lay-
ers. The transfer rate of BDP across the cell layer after deposition of the glycerol-free particles was
proportional to the mass deposited. In comparison, the transfer of BDP from the glycerol-containing for-
mulation was independent of the mass deposited, suggesting that the release of BDP is modiﬁed in the
presence of glycerol. The rate of BDP transfer (and the extent of metabolism) over 2 h was faster when
delivered in glycerol-free particles, 465.01 ng ± 95.12 ng of the total drug (20.99 ± 4.29%; BDP plus active
metabolite) transported across the cell layer, compared to 116.17 ng ± 3.07 ng (6.07 ± 0.16%) when the
equivalent mass of BDP was deposited in glycerol-containing particles. These observations suggest that
the presence of glycerol in the maturated aerosol particles may inﬂuence the disposition of BDP in the
lungs.
 2013 Elsevier B.V. All rights reserved.1. Introduction
The efﬁcacy of inhaled corticosteroids for the treatment of asth-
ma is well documented, with national and international treatment
guidelines recommending their use for control of mild persistent,
moderate and severe asthma [1,2]. Beclomethasone dipropionate
(BDP) is one of the most commonly used corticosteroids in the
treatment of asthma and, after deposition in the lung, undergoes
rapid metabolism via esterase enzymes to the active metabolite,
beclomethasone-17-monopropionate (BMP) [3]. Several devices
have been developed to deliver BDP to the pulmonary system
including nebulisers, dry powder inhalers and pressurised metered
dose inhalers (pMDI). pMDIs are the most common devices fordelivery of BDP with marketed products including solution-based
inhalers, e.g. QVAR by 3M Ltd. and Clenil by Chesi Ltd. (also lic-
enced as Sanasthmax and Becloforte) and suspension inhalers,
e.g. Becotide by GSK Ltd.
Historically, BDP pMDIs were formulated in chloroﬂuorocarbon
(CFC) propellant; however, with the regulatory phase out of CFCs,
reformulation in more environmental friendly hydroﬂuoroalkanes
(i.e. HFA 134a and 227) was undertaken. During the CFC–HFA tran-
sition, different reformulation approaches were explored resulting
a plethora of patents within the ﬁeld [4]. For example, BDP was for-
mulated as an ultraﬁne inhalation aerosol by solubilising the drug
in an ethanol-HFA 134a-based system [5]. Similarly, Modulite™
technology utilised an ethanol-HFA-based solution, but addition-
ally incorporated non-volatile components, such as glycerol, to
generate a larger mass median aerodynamic diameter (MMAD),
equivalent to that of the original CFC-based systems [6]. While
the former approach required extensive clinical trials due to differ-
ent regional lung deposition [7], the Modulite technology was
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formulations.
Several clinical studies have evaluated the ultraﬁne and Modu-
lite products and compared these to suspension CFC formulations
in terms of pharmacokinetics (systemic exposure) and clinical efﬁ-
cacy [3]. The ultraﬁne BDP formulations with a mass median aero-
dynamic diameter (MMAD) ca. 1.1 lm resulted in greater systemic
uptake and area under the curve (AUC) blood plasma concentra-
tions compared to the larger Modulite (MMAD ca. 2.6 lm) or CFC
formulations (MMAD ca. 4 lm) [3]. The area under the plasma con-
centration curve for the BMP in the Modulite formulations was
reported to be markedly different than QVAR, but not dissimilar
to the CFC formulations even though the MMAD’s were different
[8]. In addition, the Modulite formulations were shown to have
similar clinical outcomes to CFC formulations in terms of Forced
Expiratory Volume and morning serum cortisol concentrations
[9]. A recent review by Derom and Pauwels has summarised
clinical studies utilising BDP in different HFA formulations [3];
however, while these studies provide an insight into the pharma-
cokinetics and dynamics of HFA BDP systems, direct comparison
between two formulations are difﬁcult due to the nature of the
study designs.
Interestingly, ex vivo and in vitro studies comparing ultraﬁne
and Modulite-based pMDIs have shown signiﬁcant differences in
drug disposition [10,11]. A study by Freiwald et al., employing an
extracorporally ventilated and re-perfused human lung lobe,
showed that Modulite pMDI formulations had a signiﬁcantly
slower tissue penetration rate that could be attributed to the par-
ticle topology and dissolution rate [11]. A subsequent study by
Grainger et al. produced similar ﬁndings using an in vitro Calu-3
epithelial cell line-based respiratory drug absorption model and a
Franz diffusion cell method to measure dissolution [10]. Particles
generated from QVAR (containing HFA, BDP and ethanol) and
Sanasthmax (containing HFA, BDP, ethanol and glycerol as a par-
ticle performance modiﬁer) products were compared in terms of
their dissolution and transport across an air interface Calu-3 cell
line after aerosol deposition. The particles generated by the QVAR
formulation dissolved more rapidly and resulted in more rapid
transport across the epithelial cell layer; however, this difference
could not be attributed to a single particle property, since the par-
ticle size (MMAD QVAR = 1.1 lm; Sanasthmax = 2.8 lm) crystallin-
ity and non-volatile excipients (i.e. only Sanasthmax contained
glycerol) varied [10].
Current approved approaches to assess bioequivalency of oral
inhaled products include the following: unit dose sampling, cas-
cade impaction, spray pattern and plume geometry. There are,
however, general issues regarding the in vitro tests [12]. Cascade
impaction techniques are useful for general understanding of lung
deposition; however, the results are not well correlated with regio-
nal lung deposition and the fate of particles deposited on the air-
way epithelium, the ﬁst barrier encountered by microparticles
after inhalation.
In order to study how individual inhaler formulation variables
affect the biopharmaceutical performance of the particles gener-
ated, it is important that each variable is studied in isolation.
The presence of glycerol as a non-volatile additive in the formu-
lation is interesting since glycerol is a common excipient used in
many areas of drug delivery. For example, glycerol is routinely
used as emollient, humectant, gel vehicle, plasticiser, taste
masker, transdermal patch additive and osmotic agent [1,2,13].
Glycerol has a relatively low diffusivity when compared to an
aqueous solution [3,14]. Thus, the inﬂuence of glycerol on drug
transport across the respiratory epithelium would be interesting
and provide important information regarding the potential effect
on bioavailability.Two solution-based pMDIs with identical aerodynamic proper-
ties and aerosol dosimetry, but whose particles contained either
drug alone or drug and glycerol at a 1:1 ratio have been developed
[15]. Semi-empirically derived equations were used to relate HFA,
ethanol, non-volatile components and valve components variables
to the aerosol particle size distribution and formulate solution
pMDIs with equivalent ﬁne particle doses (65 lm) and MMAD.
These inhalers generated particles with very different physico-
chemical properties: while the particles from each inhaler formu-
lation were amorphous, the morphology and thermal properties
of the glycerol-containing particles were signiﬁcantly different
than those of the glycerol-free particles.
Following the successful formulation and characterisation of
two formulations that had identical aerosol proﬁles, this article
investigates the role of glycerol on the dissolution and absorptive
transport of BDP across the respiratory epithelium using an air
interface Calu-3 cell-based drug absorption model.2. Materials and methods
2.1. Materials
BDP was supplied by Teva Pharmaceuticals (Harlow, UK). Actu-
ators and pMDI valves were provided by Bespak Ltd. (Norfolk, UK).
pMDI cans were provided by Presspart Ltd. (Lancashire, UK). Etha-
nol (P99.5%) was supplied by Sigma-Aldrich (Gillingham, UK) and
glycerol (P99%) provided by Sigma-Aldrich (Gillingham, UK).
HFA134a (1,1,1,2-tetraﬂuoroethane) and HFA 227 (1,1,1,2,3,3,3-
heptaﬂuoropropane) were supplied by (Mexichem Fluor, Runcorn,
UK).
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM, without phenol
red and L-glutamine, including sodium bicarbonate and 15 mM
HEPES), non-essential amino acids solution (x100), CelLytic™ M
Cell Lysis (50 mM Tris–HCl, pH 8, 150 mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS), mammalian protease inhibitor
cocktail, HEPES (4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic
acid sodium salt) and (±)-a-Tocopherol (Vitamin E) were pur-
chased from Sigma-Aldrich (Sydney, Australia). Phosphate buffered
saline (PBS), Foetal bovine serum (FBS), L-glutamine solution
(200 mM), Trypsin-EDTA solution (2.5 g/L trypsin, 0.5 g/L EDTA)
and Hank’s balanced salt solution (HBSS) were obtained from Invit-
rogen (Sydney, Australia). The Calu-3 cell line (HTB-55) was ob-
tained from American Type Cell Culture Collection (ATCC,
Rockville, USA) and was used between passages 35 and 40. Trans-
well cell culture inserts (0.33 cm2 polyester, 0.4 lmpore size) were
purchased from Corning Costar (Lowell, MA, USA). Sterile culture
plastic-wares were obtained from Sarstedt (Adelaide, Australia).
All solvents and chemicals were analytical grade and were sup-
plied by Sigma (Sydney, Australia). Water used throughout the
experiment was puriﬁed by reverse osmosis (MilliQ, Sydney,
Australia).2.2. Preparation of solution pMDIs with equivalent aerodynamic size
distributions
Formulations exhibiting equivalent MMAD, geometric standard
deviations (GSDs) and stage deposition proﬁles were prepared
using methods described previously [15]. The formulations were
designed such that evaporation of the volatile components would
result in aerosol particles containing either drug alone or drug with
50% w/w glycerol, thus allowing the effect of glycerol on dissolu-
tion and transepithelial transport to be studied (Table 1).
These two formulations are referred to ‘glycerol-free’ and ‘glyc-
erol-containing’ throughout the remainder of the text.
Table 1
Formulation and device speciﬁcation for the glycerol-containing and glycerol-free









BDP 0.35 60.6 0.43 59.3
Ethanol 15.00 2595.0 15.00 2092.5
Glycerol 0.35 60.6 0.0 0.0
HFA 134a 84.3 14583.9 0.0 0.0
HFA 227 0.0 0.0 84.57 11798.2
Bespak metering chamber (ll) 63 ll 50 ll
Bespak actuator oriﬁce diameter (mm) 0.30 0.33
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Calu-3 cell monolayer was grown in Dulbecco’s Modiﬁed Eagle’s
medium: F-12 containing 10% (v/v) foetal calf serum, 1% (v/v) non-
essential amino acid solution and 1% (v/v) L-glutamine solution.
The cells were seeded on Transwell inserts at a density of
5  105 cells  cm2 and maintained in 95% rH air supplemented
with 5% CO2 at 37 C. After 24 h in culture, the medium covering
the cells in the apical chamber was removed and the cells were
allowed to differentiate under the air interface condition. Drug
permeability studies were conducted on cell layers between 12
and 14 days after seeding. This period was previously determined
as optimal by Haghi et al. [6,16].
The transepithelial electrical resistance (TEER) of the Calu-3
monolayer was evaluated before and after the transport study to
conﬁrm that cell layer integrity was maintained over the course
of the experiment. To enable TEER measurements, 100 lL pre-
warmed medium was added to apical chamber and TEER was
measured with a voltohmmeter (EVOM with STX-2 chopstick elec-
trodes, World Precision Instruments, FL, USA). TEER measurements
at the end of each experiment showed no signiﬁcant differences
when compared to pre-experiment values (ANOVA p < 0.05).2.4. In vitro cell deposition studies
Deposition of particles generated by each formulation onto the
cell layers and measurement of transepithelial BDP ﬂux was con-
ducted using methods adapted from Grainger et al. [10,17]. In this
method, the twin stage impinger (TSI) (Radleys, Essex, UK) was
modiﬁed to accommodate a Transwell insert in the lower chamber.
The assembled TSI was then connected to a Rotary vein pump
(GAST, Michigan, USA). The pMDIs containing the BDP formula-
tions were connected to the TSI and the ﬂow rate adjusted to
60 L min1 using a ﬂow metre (Model 4040, TSI Model Instru-
ments, Germany). The pMDIs were then actuated a set number of
times (ranging from 2 to 10 shots; to allow the deposition of equiv-
alent total drug mass or total particle number on the cell layer).
After particle deposition, the Transwell was removed from the
TSI, the outer surface cleaned of the adhering particles and trans-
ferred into a well containing 300 lL modiﬁed buffer (HBSS supple-
mented with HEPES (1% v/v), vitamin E (1% v/v) and ethanol 97%
(1% v/v) at pH 7.4) to measure the BDP transfer. The cells were
pre-equilibrated in the modiﬁed buffer for 1 h prior to particle
deposition. At each time point, the cells were moved to a new well
containing fresh medium. At the end of 4-h experiment, the med-
ium from the wells was collected into vials and the wells were
rinsed with 300 lL of ether to recover any BDP/BMP adhered to
the plastic. A ﬂuticasone internal standard for high performance
liquid chromatography mass spectrometry (HPLC–MS) and ether
used for rinsing were also added to the samples. After 4 h ofexperiment, the surface of the monolayer was washed and the
sample collected for analysis of drug content. The cell layer was
then harvested for analysis of the drug inside the cells. The method
has been described previously by Haghi et al. [3,18]. Brieﬂy, the
cells were harvested using trypsin EDTA solution and lysed using
Cell lytic and protease inhibitor cocktails. The samples were vor-
texed and left in freezer at 70 C. Once the aqueous phase was
frozen, the ether phase was removed and evaporated. The samples
were reconstituted in mobile phase and analysed with HPLC–MS.
The amount of BDP deposited on the cell layers was veriﬁed in
preliminary studies by depositing particles onto cell-free Trans-
wells and immediately washing to recover the BDP. In the trans-
port experiments, the cumulative amount of BDP transported
across the cell layer was added to the amount of BDP within and
on the surface of the cell layer. Thus, the total amount of BDP
deposited and the percentage BDP transported were calculated
(metabolism of BDP to its major metabolite BMP occurs with 1:1
stochiometry and was also accounted for and used to calculate
the ‘total’ amount of BDP deposited and ‘total drug’ transported).
The total drug (BDP + BMP) recovered during experiments was
consistent with the amount of BDP deposited onto cell-free Trans-
wells in the dose-ﬁnding studies.
2.5. High performance liquid chromatography mass spectrometry
(HPLC–MS)
An HPLC–MS method was used to determine the concentration
of BDP and the primary metabolite from in vitro cell samples.
Brieﬂy, a Thermo Scientiﬁc TSQ quantum access max system was
utilised comprising of a Transcend 600 series TLX1 (Thermo Scien-
tiﬁc Ltd., Australia).
A 75 mm  2.1 mm (2.7 lm Fused-Core particle platform)
Supelco Ascentis Express C18 column was used for separation.
After the ether extraction process described previously, the dry
analytes were reconstituted with 200 lL mobile phase consisting
of (80:20%, v/v) methanol: 10 mM aqueous ammonium acetate
solution and the internal standard (ﬂuticasone) were added to each
sample. Each sample was injected (20 lL injection volume) onto
the column, operating at a ﬂow rate of 0.2 mL min1.
The mass spectrometer was operated in a positive electrospray
ionisation mode, with a 5 kV capillary, a 17 V cone, Vaporizer Tem-
perature and Ion Transfer Tube Temperature of 382 C and 250 C,
respectively. The selective reaction-monitoring (SRM) mode was
used for mass spectrometry detection. Parent ion channels of
501, 521 and 465m/z and daughter ion channels of 313, 319 and
279m/z were used for ﬂuticasone, BDP and BMP, respectively.
2.6. Statistical analysis
Data were analysed for statistical signiﬁcance using the SPSS
Statistics 17.0 software package (SPSS Inc., Chicago, IL, USA).
One-way ANOVA (with Tukey’s post hoc analysis) was utilised
to test for signiﬁcance. Data are represented as mean ± SD of
minimum ﬁve independent experiments. Differences were consid-
ered signiﬁcant when p < 0.05.3. Results and discussion
The surface of the airway epithelium is a complex pseudo-strat-
iﬁed structure made up of a number of differentiated cell types and
a surface lining ﬂuid containing mucus and phospholipids. The sur-
face area of the epithelium is large, and deposition of unagglomer-
ated inhaled drug particles is likely to be a discrete event. In the
tracheobronchial region, the volume of the mucosal lining liquid
is low and the layer of mucus is of an equivalent thickness to the
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may therefore be envisaged that when a particle deposits, the sur-
rounding mucus rapidly becomes saturated with drug and passive
absorptive transport is dependent on the properties of the drug
and epithelium (i.e. partition and diffusivity of drug via the trans-
cellular and paracellular routes). However, this process becomes
more complicated when delivering a semi-solid particle such as
the glycerol formulation, which contains BDP glycerol at a 1:1
mass ratio as the effect of the excipient, must also be considered.
This experiment was designed, so that the aerodynamic size
distribution of the BDP particles from the glycerol-free and glyc-
erol-containing formulations was equivalent, allowing for a direct
comparison of the inﬂuence of glycerol on transepithelial drug
transport. The MMAD of the glycerol-free and glycerol-containing
formulations, measured via ACI stage deposition data, was
2.4 ± 0.1 lm and 2.5 ± 0.2 lm, respectively (n = 3). No signiﬁcant
difference in stage-by-stage deposition or ﬁne particle fraction/
mass was observed between the two formulations used [8,15]. It
is important to note, however, that for the mass of drug emitted
by both formulations to be similar, the number of particles (and
formulation mass, including excipient) would be different. Since
the number of particles or total drug mass on the epithelial surface
may affect drug transport, matched doses of each were incorpo-
rated into the study design.3.1. Dosimetry: particle number versus mass of BDP delivered
The number of actuations into the TSI was optimised to deposit
equivalent particle number or equivalent BDP mass onto the Trans-
well or Calu-3 cell layer. It is important to note that the exact num-
ber of particles can only be estimated, as the actual distribution of
particles within the respective particle size classes is not precisely
known. However, the particle size distribution MMAD and GSD for
each formulation were not signiﬁcantly different making compar-
ison by mass possible [15]. After the evaporation of the volatile
HFA and ethanol components, both the glycerol-free and glyc-
erol-containing particles had similar size distributions and deliv-
ered equivalent BDP mass per actuation. Thus, aerodynamic
deposition will result in twice the number of glycerol-containing
particles compared to the glycerol-free formulation since glycerol
accounts for 50% w/w of the total particle mass. This concept is
illustrated in (Fig. 1).
The inﬂuence of glycerol on the disposition of BDP was investi-
gated by delivering an equivalent mass of BDP from each formula-
tion (2215 ng ± 271 ng of BDP from the glycerol-free formulation
compared to 1909 ng ± 249 ng of BDP from the glycerol-containing
formulation). The effect of depositing equivalent particle numbers
was investigated by delivering 2215 ng ± 271 ng BDP from the
glycerol-free formulation compared to 826 ng ± 138 ng BDP from
the glycerol-containing formulation. In addition, as a control for
the effect of mass of BDP deposited (i.e. 1000 ng and 2000 ng)
versus the formulation effect, a lower deposition of glycerol-free
formulation was also performed (1024 ng ± 142 ng BDP).Fig. 1. Schematic showing glycerol-free particles (red circles) and glycerol-containing p
Calu-3 cell monolayer; the proportion of red represents the mass of BDP delivered in the e
compared for equivalent dose (left) and equivalent particle number deposition (right).
referred to the web version of this article.)The density of particles on the epithelial cell layer surface
was estimated to address concerns regarding particle overload.
Taking the ‘worst case’ scenario by considering the surface area
of the cell monolayer (0.33 cm2) and assuming a particle diame-
ter of 2.5 lm (based on the MMAD), the lowest theoretical par-
ticle density of 1260 kg m3 (i.e. that of glycerol [8,13]) and a
deposited mass of 5 lg (i.e. twice that of the maximum BDP
mass deposited), the coverage of the cell surface would be
7%. Although this calculation is based on spherical particle
geometries and their projected surface area, it is clear that none
of the doses utilised would overload the cells or layer particles
upon each other.3.2. Kinetics of BDP transport across Calu-3 cells
The inﬂuence of depositing BDP (1000 ng or 2000 ng in
glycerol-free or glycerol-containing particles) on the mass or
percentage transport of BDP across the Calu-3 cell line was
studied.3.2.1. BDP transport after deposition of glycerol-free particles
The glycerol-free formulation delivered BDP across the cell
layer in proportion to the mass of drug deposited onto the cells,
with the rate of transport remaining linear irrespective of the mass
of BDP deposited (i.e. constant ﬂux, zero-order kinetics). Thus,
35.5 ± 5.8 ng and 101.6 ± 31.5 ng of BDP was transported over 2 h
following the deposition of 1000 and 2000 ng BDP, respectively.
These results are consistent with particles being depositing dis-
cretely at the epithelia and immediately saturating the local
mucus-rich cell lining ﬂuid. The rate of drug transport was directly
proportional to the number of particles deposited discreetly across
the epithelia, i.e. the percentage of BDP transported was the same
irrespective of the amount of BDP deposited (3.3–4.1% over 2 h;
Fig. 2).3.2.2. BDP transport after deposition of glycerol-containing particles
In contrast to the non-glycerol formulation, the transport of
BDP from the glycerol-containing formulation was independent
of the mass of BDP deposited (Fig. 2). Approximately 50 ng of
BDP was transported across the cell layer (51.2 ± 3.1 ng and
58.0 ± 10.0 ng) after deposition of particles containing 1000 ng
and 2000 ng BDP, respectively. Interestingly, as with the glyc-
erol-free formulation, the transport rate was linear (i.e. constant
ﬂux suggesting zero-order kinetics); however, the mechanism of
drug dissolution/release at the epithelial surface was clearly differ-
ent. Since the mass transport of BDP was independent of the
deposited dose, the percentage transported varied signiﬁcantly
4.9 ± 0.1% and 2.2 ± 0.0% in 2 h following deposition of glycerol-
containing particles delivering 1000 ng and 2000 ng BDP,
respectively. This constant mass transfer of BDP from glycerol-con-
taining particles suggests a signiﬁcant effect of glycerol upon the
BDP availability at the cellular level.articles (blue and red circles). The circles represent the particles deposited on the
xperiment (1000 ng for a full circle; 500 ng for a semi-circle). The formulations were
(For interpretation of the references to colour in this ﬁgure legend, the reader is
Fig. 2. Comparison of the amount and % of BDP transported over time as a function of the total mass of BDP deposited on air interfaced Calu-3 cell layers (n = 5). BDP aerosols
were generated from glycerol-free or glycerol-containing solution pressurised metered dose inhalers and particles were deposited onto cell layers in the second chamber of a
twin stage impinger. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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TEER measurements at the end of each experiment showed no
signiﬁcant differences when compared to pre-experiment values
(ANOVA p < 0.05).
The transport kinetics of BDP across the Calu-3 cells were
reanalysed to compare BDP transport from glycerol-free and glyc-
erol-containing particles in terms of mass and percentage trans-
port after deposition of an equivalent mass of BDP (2000 ng) or
an equivalent number of particles from each formulation deposited
onto the cells (Fig. 3).
The transport rate of BDP was higher in the absence of glycerol
in the particles (Fig. 3A); this was clearly seen when presented as
the percentage transport data with 4.1 ± 0.8% of BDP from the glyc-
erol-free formulation transported to the basal compartment over
2 h compared to 2.2 ± 0.0% from the glycerol formulation
(Fig. 3B). The mass and percentage of BDP transported when an
equivalent number of particles was deposited on the cells
(2000 ng BDP in the glycerol-free particles compared with
1000 ng BDP in the glycerol-containing particles) revealed a
higher transport rate over 2 h for BDP from the glycerol-free for-
mulation compared to the glycerol-containing formulation
(Fig. 3C). Incidentally, the percentage BDP transport from both
these formulations was similar (Fig. 3D; 4.06 ± 0.77% and
4.91 ± 0.10% for BDP from non-glycerol and glycerol formulations,
respectively). Interestingly, these proﬁles were derived from the
equivalent number of glycerol-free particles delivering double
the mass of BDP compared to the glycerol-containing particles.
3.4. Metabolism of BDP to BMP and ‘total drug’ transport
In addition to the transport of BDP, it is important to
consider metabolism by the respiratory epithelial cells. BDP is
metabolised to beclomethasone 17-monopropionate (17-BMP),
beclomethasone 21-monopropionate (21-BMP) and beclometha-sone (BOH). Previous studies have shown that the relative binding
afﬁnity of 17-BMP for the cytoplasmic glucocorticoid receptor of
human lung is 25 times greater than that of the parent drug
BDP [3,20], whereas 21-BMP is practically inactive. The amount
of 17-BMP generated and transported in the experiments was pro-
portional to the levels of BDP transported across the cells (Fig. 4),
suggesting that the differences in metabolism/transport of BDP in
the presence or absence of glycerol reﬂect the availability of BDP
from these formulations (i.e. the action of glycerol in reducing
transepithelial ﬂux of BDP also results in decreased drug exposure
to metabolising enzymes in the cell cytoplasm). This is consistent
with the amount of BDP within the cells at the end of the
experiments: cells exposed to glycerol-free formulation contained
50.7 ng ± 28.8 ng and 112.3 ng ± 26.6 ng after the deposition of
1000 ng and 2000 ng BDP, respectively, whereas there was no
signiﬁcant difference in the amount of BDP recovered from the
cells was observed for the glycerol formulation (33.9 ng ± 13.3 ng
and 28.8 ng ± 7.1 ng for 1000 ng and 2000 ng BDP deposited,
respectively).
Interestingly, there was an appreciable lag of P60 min, before
BMP appeared in the receiver chamber of the Transwell diffusion
apparatus (i.e. on the contralateral side of the Calu-3 cell layer after
BDP deposition to the apical surface). This may simply reﬂect the
time taken for appreciable levels of 17-BMP to be generated, accu-
mulate and efﬂux from the cells. However, BMP appearance in the
basal compartment may depend, in part, on the binding afﬁnity
and saturation of the glucocorticoid receptor in the cells (an effect
that would not be seen with BDP since the pro-drug has a much
lower receptor afﬁnity than 17-BMP [11,19]). It is also interesting
to speculate whether glycerol may interact with BDP sterically to
hinder metabolism by reducing the access of esterase enzymes to
the ester carbonyl in the BDP molecule [10,11,21].
When ‘total drug’ transport is considered (i.e. combining
17-BMP and the BDP data), the trends discussed for BDP transport
were mirrored (Fig. 5). A mass of 465.0 ng ± 95.1 ng of the total
Fig. 3. Comparison of the amount and % of BDP transport over time. (A) Amount of BDP transported after deposition of equivalent drug mass, (B) % of BDP transported after
deposition of equivalent drug mass, (C) amount of BDP transported after deposition of equivalent particle number, (D) % of BDP transported after deposition of equivalent
particle number (n = 5). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. Comparison of the amount and % of 17-BMP transported across Calu-3 cell layers in 2 h after deposition of BDP from glycerol-free and glycerol-containing pMDI, (A)
Amount of 17-BMP transported from equivalent deposited doses of BDP, (B) % of 17-BMP transported from equivalent deposited particle number (n = 5, mean ± SD). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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glycerol-free formulation compared to 116.17 ng ± 3.07 ng total
drug (6.07 ± 0.16%) for the glycerol-containing formulation over
the duration of the experiment (Fig. 5A and B). Similarly, total drug
transport after deposition of equivalent particle number (Fig. 5C
and D) showed that total drug transport from the glycerol-free par-
ticles was 465.01 ± 95.12 ng (20.99 ± 4.29% of total deposition)
compared with 169.83 ± 39.52 ng (20.56 ± 4.78%) from the glyc-
erol-containing formulation. As with the BDP and BMP transport
data (in Sections 3.2 and 3.3), it is clear that the total amount of
drug transported across the epithelia (BDP and BMP) is dependent
on the formulation deposited.3.5. Effect of glycerol on BDP availability
In conventional gel-based formulations, glycerol is often incor-
porated in an aqueous solution at concentrations ranging from
0.5% to 50% w/v [10,13]; however, in the formulation studied here,
the dried aerosol particles would be solid or semi-solid with a 1:1
mass ratio of amorphous BDP and glycerol. The presence of glyc-
erol appeared to affect the release of drug from the deposited par-
ticle, with resultant consequences for the rate of transport across
the epithelium. We have previously reported that the presence of
glycerol in the aerosolised droplets affected the physicochemical
properties of the particles generated after evaporation of volatile
Fig. 5. Comparison of the total drug (BDP and17-BMP) and % total drug transported across Calu-3 cells after deposition of BDP from glycerol-free and glycerol-containing
pMDI (A) Total amount transported from equivalent deposited mass of BDP, (B) Total % transported from equivalent deposited mass of BDP, (C) Total amount transported
from equivalent particle numbers deposited, (D) Total % transported from equivalent particle numbers deposited (n = 5, mean ± SD). (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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brane in a Franz diffusion cell [10,15].
Glycerol is able to hydrogen bond intra-molecularly and inter-
molecular with BDP and water. Molecular dynamic stimulations
and infrared spectroscopy have provided evidence of glycerol and
water hydrogen bonding patterns [22]. It has been shown by infra-
red spectroscopy that increasing glycerol concentration causes a
growth in the ﬁrst hydration shell since more bulk water molecules
are required for the solvation of glycerol. The surface of the epithe-
lial cell layers used here provides a ﬂuid restricted, glycoprotein
rich environment, which is representative of the surface of the tra-
cheobronchial region of the lung. The amount of ﬂuid on the sur-
face of air interfaced Calu-3 cells has been previously estimated
at around 3.44 lL over a 0.33 cm2 area [17]. The amounts of
drug/glycerol deposited in this study may have depleted the bulk
water pool to a point there are insufﬁcient free water molecules
to transfer to the ﬁrst hydration shell with the result that water
is no longer available to solvate the glycerol molecules and the rate
of BDP dissolution and diffusion is diminished.
It has also been shown that as the glycerol concentration
increases, water molecules in the ﬁrst hydration shell are more
likely to be found around glycerol OH groups. This implies that
the CH groups of BDP are surrounded by glycerol in an arrange-
ment known as alkyl backbone clustering. At higher concentrations
of glycerol, water molecules concentrate around the polar groups
of glycerol causing the alkyl groups of glycerol to self-associate
[22] and glycerol–glycerol hydrogen bonds become dominant. This
may result in the formation of a gel layer consisting of structured
Water–Glycerol–BDP, the properties of which dictate the kinetics
of drug release.
In general, the results of this study are in good agreement with
previous in vitro [10] and ex vivo [11] studies on commercial prod-
ucts QVAR and Sanasthmax. However, in the earlier investigations,
the speciﬁc effect of glycerol could not be delineated from othervariables in the particle (especially size). In this study, the aerody-
namic diameters of the glycerol and non-glycerol formulation were
matched. Although clear differences in in vitro epithelial transport
were observed, the availability of BDP from a glycerol-rich gel in a
ﬂuid restricted environment is the likely reason for the observa-
tions as this effect was also seen in the cell free (Franz diffusion
apparatus) dissolution studies. Future studies should investigate
the inﬂuence of glycerol on particle dissolution and drug diffusion
at a molecular level and investigate the absorption of BDP in vivo
after delivery of aerosols generated from these two formulations.4. Conclusions
Two formulations with identical MMADs, containing BDP alone
or BDP/glycerol in a 1:1 ratio, were deposited onto air interfaced
Calu-3 epithelial cell layers. Signiﬁcant differences in the rate of
drug transport were found, with BDP delivered by the glycerol-free
formulation transferring more rapidly across the cell layers. Inter-
estingly, there was a concomitant increase in the extent of metab-
olism compared to the glycerol-containing formulation. It was
concluded that despite the aerodynamic equivalence of the two
formulated products, in this model, the presence of glycerol in
the deposited particles retarded the availability of BDP for trans-
port across in vitro respiratory epithelial cells. Such observations
would suggest that while the two formulations are bio-equivalent
in terms of respiratory deposition their bio-equivalency in terms of
drug absorption might differ in vivo.References
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